Hormone testing for perimenopause can provide useful clinical information, but no single blood test confirms the transition. Perimenopause is diagnosed clinically, based on symptoms, menstrual changes, age, and medical history, with lab work playing a supporting role in specific situations. For women in their 40s and early 50s experiencing hot flashes, irregular cycles, or sleep disruption, the question isn't whether to test but rather which tests are worth ordering, when to draw the sample, and how to interpret results that may shift from one month to the next. A direct-pay lab panel ordered alongside a clinical evaluation gives a clearer starting point than a single snapshot taken without context.
Roughly 8 million U.S. women are in perimenopause at any given time, according to a Komodo Health analysis of nearly 29 million women ages 45-51 (Komodo Health, 2023). About 1.3 million women enter menopause each year, and the average age of natural menopause is 51. Despite those numbers, a 2024 analysis of the Menopause Society directory found fewer than 1,400 Menopause Society Certified Practitioners across the country, a ratio of roughly 1 per 29,500 women in the target age range (AcademyHealth, 2024). That gap helps explain why so many women turn to online searches for guidance on perimenopause blood tests.
This article explains which hormones are commonly tested during perimenopause, when testing is clinically useful, how to time a blood draw for the most accurate results, and what the evidence says about the limits of laboratory-only diagnosis.
What Does "Hormone Testing For Perimenopause" Actually Mean?
Most women searching for hormone testing for perimenopause want a lab test that confirms the transition has started. In clinical practice, that test doesn't exist.
Perimenopause describes the years of hormonal change leading up to menopause. During this window, the ovaries produce estrogen and progesterone on an increasingly unpredictable schedule. A blood sample drawn on Tuesday may look entirely different from one drawn 2 weeks later, because the ovaries can swing from high output to low output within a single cycle (Santoro et al., 2021).
The European Society of Endocrinology (ESE) stated in its 2025 clinical practice guideline that perimenopause and menopause should be diagnosed without laboratory tests in otherwise healthy women aged 45 and older, on the basis of vasomotor symptoms, irregular periods, and amenorrhea (Lumsden et al., 2025). The Menopause Society's 2022 Hormone Therapy Position Statement and ACOG's guidance align with this approach.
That said, hormone testing isn't useless. It fills a different role than most people expect.
When Is Hormone Testing Clinically Useful?
Providers order perimenopause blood work for specific clinical questions, not for a general confirmation of the transition.
Testing is most valuable in these situations:
Women under 40 with symptoms suggesting premature ovarian insufficiency (POI) may benefit from FSH and estradiol testing to help differentiate POI from other causes of cycle disruption. POI affects about 1 in 100 women under 40 (Touraine et al., 2024). Early menopause (ages 40-45) affects roughly 5% of women, and hormone testing can clarify the picture in that age window as well.
Women on hormonal contraception who develop perimenopausal symptoms present a diagnostic challenge, because the contraceptive suppresses natural hormone production. FSH and estradiol levels measured while on a combined pill may not reflect natural ovarian function and are generally considered difficult to interpret. For women under 40 in this situation, guidelines suggest a washout period of at least 6 weeks off the combined pill before testing, under the direction of a prescribing provider (Lumsden et al., 2025).
Women already on HRT may benefit from estradiol monitoring to help assess whether serum levels are appropriate for their prescribed therapy. The Menopause Society's 2022 Position Statement notes that measurement of blood estradiol levels can identify women who absorb transdermal estrogen poorly or who need dose adjustments, particularly those using patches or gels (Menopause Society, 2022).
Ruling out conditions that mimic perimenopause, especially thyroid disease, is another standard use of blood work. Hypothyroidism and hyperthyroidism share symptoms with perimenopause, including fatigue, mood changes, irregular periods, and temperature sensitivity. A TSH test can help distinguish between the two conditions.
Which Hormones Are Tested During Perimenopause?
The most commonly ordered tests during a perimenopause evaluation each measure something different, and each has specific limitations.
Follicle-stimulating hormone (FSH) is the test most women associate with perimenopause. FSH rises when the ovaries become less responsive to brain signals. A single elevated reading can occur in a healthy premenopausal cycle and doesn't confirm perimenopause by itself. European guidelines recommend two FSH measurements taken 4-6 weeks apart for women under 45 or those being evaluated for premature ovarian insufficiency (Lumsden et al., 2025).
Estradiol (E2) reflects the primary form of estrogen produced by the ovaries. During perimenopause, estradiol can be low, normal, or paradoxically elevated from cycle to cycle. This variability is exactly why a single reading rarely tells a clear story.
Progesterone is best measured in the mid-luteal phase (about days 19-21 of a regular cycle). A low progesterone reading at this point suggests that ovulation was weak or absent, one of the early hormonal shifts that may signal the onset of perimenopause (Prior, 2011).
Luteinizing hormone (LH) works alongside FSH to regulate ovulation. It's rarely useful on its own for perimenopause assessment but may be included in broader panels.
Anti-Mullerian hormone (AMH) estimates ovarian reserve (the remaining egg supply). AMH doesn't confirm perimenopause, but a very low AMH in a symptomatic woman under 40 supports a POI evaluation. The Menopause Society doesn't recommend AMH for routine perimenopause assessment.
Testosterone is relevant for women reporting low libido, fatigue, or brain fog during the transition. No FDA-approved testosterone product exists for women in the U.S., but the Global Consensus Position Statement on testosterone therapy for women (endorsed by the International Society for the Study of Women's Sexual Health) supports off-label use of physiologic doses for diagnosed hypoactive sexual desire disorder (HSDD) in postmenopausal women after appropriate assessment (Davis et al., 2019). Testing may help establish a baseline and inform dosing decisions, which is particularly important because women's testosterone levels are far lower than men's and require more precise measurement.
|
Hormone |
What It Measures |
Best Timing |
Clinical Limitation |
|
FSH |
Ovarian responsiveness to brain signals |
Days 2-5 (early follicular phase) |
Fluctuates cycle to cycle; one reading is not diagnostic |
|
Estradiol (E2) |
Primary ovarian estrogen |
Days 2-5 or 19-21 depending on the clinical question |
Can be low, normal, or high on any given day in perimenopause |
|
Progesterone |
Whether ovulation occurred |
Days 19-21 (mid-luteal phase) |
Only informative in the second half of a regular cycle |
|
LH |
Ovulation regulation |
Days 2-5 |
Rarely useful alone for perimenopause |
|
AMH |
Ovarian reserve |
Any day (not cycle-dependent) |
Not used to confirm perimenopause; relevant for POI evaluation |
|
Testosterone |
Androgen status |
7-10 a.m. (morning draw) |
No FDA-approved product for women; levels vary by assay |
|
TSH |
Thyroid function |
Any time (fasting preferred) |
Rules out thyroid disease; does not assess menopausal status |
How to Time a Perimenopause Blood Test
Timing matters more than most women realize. Hormones shift throughout the menstrual cycle, throughout the day, and throughout the perimenopausal transition itself.
If menstrual cycles are still regular, the 2 most informative windows are days 2-5 for FSH and estradiol (the early follicular phase, before ovulation) and days 19-21 for progesterone and estradiol (the mid-luteal phase, when progesterone should peak). Drawing FSH at baseline, before the ovaries have responded to the cycle's hormonal signaling, gives the cleanest read on whether that baseline is creeping upward.
Testosterone should be drawn between 7 and 10 a.m. regardless of cycle day. Research confirms diurnal variation in women's testosterone, with morning levels being highest (Algburi et al., 2023).
If cycles are irregular, there may not be a reliable "best" day. In that case, providers typically draw a panel and interpret the results against reference ranges for each stage of the transition, factoring in symptoms, age, and medical history. Providers often find that repeating the panel over several months provides more useful information than a single, precisely timed draw.
TSH can be drawn at any time and doesn't depend on cycle timing.
What Hormone Test Results Can and Cannot Tell
Hormone levels during perimenopause can fall within reference ranges even when symptoms are severe. They can also appear outside those ranges on a day when a woman feels perfectly fine.
This disconnect exists because perimenopause is defined by the pattern of hormonal change over time, not by a threshold on a single lab report. A provider experienced in perimenopause care reads the numbers in the context of the full clinical picture: which symptoms are present, when they started, how they've changed, what the menstrual history shows, and whether other conditions (thyroid disease, iron-deficiency anemia, depression, sleep disorders) could explain the same symptoms.
A normal FSH doesn't rule out perimenopause. An elevated FSH doesn't confirm it. What the number does is add one data point to a broader assessment.
This is why the major guidelines, including the Menopause Society, ACOG, and the ESE, all recommend against routine hormone testing for women over 45 with typical symptoms. The clinical history is usually enough.
For women who are starting or adjusting hormone replacement therapy, lab work fills a different, more concrete role. Estradiol levels help providers confirm the dose is producing the intended serum concentration, and follow-up panelstrack the response over time.
Tests That Rule Out Other Conditions
Part of any thorough perimenopause evaluation involves confirming that the symptoms aren't caused by something else. Perimenopause shares significant symptom overlap with several common conditions.
A thyroid panel (TSH, free T4) is the most frequently ordered alongside perimenopause testing. Thyroid disease can cause fatigue, weight changes, mood disruption, irregular periods, and temperature sensitivity, all of which overlap with the menopausal transition (Lumsden et al., 2025).
Iron studies and a complete blood count (CBC) are appropriate when fatigue is the primary complaint, or when menstrual bleeding has become heavier. Heavy perimenopausal bleeding can cause iron-deficiency anemia, which compounds fatigue regardless of hormonal status.
Prolactin testing may be considered if menstrual changes are otherwise unexplained, since elevated prolactin can suppress ovulation and disrupt the cycle independently of perimenopause.
Vitamin D is worth checking during midlife, not to assess perimenopause but because deficiency is common in this population and has been associated with fatigue, mood changes, and bone health concerns.
What Changed With the 2025 FDA Labeling Update
On November 10, 2025, the FDA initiated removal of the broad boxed warnings related to cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy products (FDA, 2025). The endometrial cancer warning remains for systemic estrogen-alone therapy. Updated labeling recommends initiating systemic HRT within 10 years of menopause onset or before age 60.
This change reflects decades of reanalysis of the original WHI trial data. The WHI long-term follow-up supported a more favorable risk-benefit profile for women who start HRT younger and closer to menopause onset (Manson et al., 2017). Separately, multiple observational meta-analyses have associated transdermal estrogen with lower venous thromboembolism risk than oral routes (Vinogradova et al., 2019).
For women approaching perimenopause, the labeling update doesn't change whether or how perimenopause is diagnosed. It does change the risk-benefit conversation about treatment once symptoms are identified. Baseline blood work, including hormone levels, a lipid panel, and thyroid and metabolic markers, helps providers assess individual risk before initiating therapy.
Compounded Hormones vs FDA-Approved Formulations
The Menopause Society's 2022 Position Statement and ACOG Clinical Consensus No. 6 (2023) both state that compounded bioidentical hormone therapy should not be prescribed routinely when FDA-approved formulations exist (ACOG, 2023). Compounded products are not FDA-approved, lack standardized labeling, and carry quality-control concerns including potential over- or under-dosing, impurities, and absence of efficacy and safety data.
FDA-approved bioidentical options, including estradiol patches and micronized progesterone (Prometrium), have been tested in controlled trials and carry labeled safety information. Salivary and urine hormone testing to guide compounded dosing is not recommended by the Menopause Society.
This distinction matters for women seeking hormone testing through any provider. The test results are only as useful as the clinical framework applied to them.
How Do Providers Identify Perimenopause Without a Lab Test?
For most women over 45 with characteristic symptoms and menstrual changes, perimenopause is recognized through clinical assessment. No lab result is required.
The clinical assessment starts with symptom history. The most commonly reported symptoms include hot flashes, night sweats, sleep disruption, mood changes, difficulty concentrating, irregular cycles, and changes in energy. About 60-80% of women experience vasomotor symptoms (hot flashes and night sweats) during the menopausal transition (Santoro et al., 2021).
Menstrual history is a primary diagnostic input. Increasing cycle variability, skipped periods, changes in flow, and shortening or lengthening of intervals all signal the transition. Providers assess these patterns against a woman's prior baseline.
Age provides context. Most women enter perimenopause in their mid-40s. Symptoms before 40 raise concern for POI and warrant testing.
Medical history, including use of hormonal contraception, prior gynecological surgery, and medications that affect bleeding, rounds out the assessment.
Blood tests are ordered selectively when the clinical picture is unclear, when symptoms occur earlier than expected, or when another condition needs to be ruled out.
When to Seek a Clinical Evaluation
Persistent or worsening symptoms that affect quality of life are a clear reason to seek evaluation. So are menstrual changes that feel significantly different from a woman's usual pattern, symptoms occurring before age 45, or uncertainty about whether the cause is perimenopause or another condition.
Providers experienced in perimenopause care can determine whether testing adds useful information, select the right markers, time the draw appropriately, and interpret results in clinical context. That structured approach avoids both unnecessary testing and missed conditions.
Women interested in hormone testing for perimenopause can order a panel through a telehealth provider who reviews results alongside symptoms and history, rather than relying on an isolated test without clinical follow-up.
Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.
FAQs
Do women need a blood test to confirm perimenopause?
Most women aged 45 and older with typical symptoms and menstrual changes don't typically need hormone testing for a perimenopause assessment. The European Society of Endocrinology's 2025 guideline, the Menopause Society, and ACOG all recommend clinical evaluation in this age group, based on symptoms, menstrual history, and medical context. Testing may be indicated when symptoms appear before age 40, when the clinical picture is unclear, or when another condition needs to be ruled out.
What is the best time to test hormone levels during perimenopause?
If cycles are still regular, FSH and estradiol are best drawn on days 2-5 of the cycle, and progesterone on days 19-21. Testosterone should be drawn between 7 and 10 a.m. regardless of cycle day. TSH can be drawn at any time. When cycles are irregular, providers rely less on cycle timing and more on hormone ratios and repeat testing over several months.
Can FSH levels confirm perimenopause?
A single FSH reading can't confirm perimenopause because FSH fluctuates from cycle to cycle during the transition. Two measurements taken 4-6 weeks apart are more informative, and they're most useful in women under 45 or in cases where the clinical picture is ambiguous. An elevated FSH supports the diagnosis when paired with symptoms and menstrual changes, but it doesn't stand alone.
Does hormonal birth control affect perimenopause test results?
Yes. Combined oral contraceptives suppress natural FSH, estradiol, and progesterone production, making blood test results difficult to interpret for perimenopause assessment. Guidelines suggest a washout period of at least 6 weeks off the combined pill before testing in women under 40 who are being evaluated for premature ovarian insufficiency, under the direction of a prescribing provider (Lumsden et al., 2025).
What blood tests should be done alongside hormone testing for perimenopause?
A TSH test is the most common addition, since thyroid disease mimics several perimenopause symptoms. Iron studies and a CBC are appropriate when fatigue or heavy bleeding is present. Prolactin may be checked if menstrual changes are otherwise unexplained. Vitamin D is worth measuring for bone health and general midlife screening.
Is there a difference between compounded and FDA-approved hormone therapy?
Compounded bioidentical hormones are not FDA-approved and lack standardized manufacturing, labeled safety data, and quality controls that FDA-approved products carry. The Menopause Society's 2022 Position Statement and ACOG's 2023 Clinical Consensus both recommend FDA-approved formulations (such as estradiol patches and micronized progesterone) when available. Salivary and urine hormone testing to guide compounded dosing is not recommended by major medical societies.
Why did the FDA change its warnings on hormone replacement therapy?
On November 10, 2025, the FDA initiated removal of the boxed warnings for cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy products (FDA, 2025). The change followed decades of reanalysis showing the original WHI results, drawn from an older population using specific formulations, did not reflect the risk profile for younger women starting therapy closer to menopause. The endometrial cancer warning remains for systemic estrogen-alone products.
Share:
Types Of Hormone Testing And When Each One Is Used
When To Retest An Abnormal Hormone Result After Bloodwork